anurajms/meta_analysis huggingface dataset:
Provide patient population that should be included in the study
Effects of total fat intake on body fatness in adults
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Cardiovascular Event Risk 6. Aged 65-79 years
Provide patient population that should be included in the study
Oral galactagogues (natural therapies or drugs) for increasing breast milk production in mothers of non‐hospitalised term infants
1. Adult 19-44 years 2. Lactating 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Breast Fed 6. Adolescent 13-18 years
Provide patient population that should be included in the study
Interventions for congenital talipes equinovarus (clubfoot)
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Young Adult 19-24 years 8. Birth to 1 mo 9. Aged 65-79 years 10. Congenital Talipes Equinus 11. Adolescent 13-18 years
Provide patient population that should be included in the study
Combination antimicrobial susceptibility testing for acute exacerbations in chronic infection of Pseudomonas aeruginosa in cystic fibrosis
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Cystic Fibrosis 8. Young Adult 19-24 years 9. Birth to 1 mo 10. Aged 65-79 years 11. Infection due to Pseudomonas Aeruginosa 12. Adolescent 13-18 years
Provide patient population that should be included in the study
Artificial corneas versus donor corneas for repeat corneal transplants
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Corneal Transplant 6. Aged 65-79 years
Provide patient population that should be included in the study
Alarm interventions for nocturnal enuresis in children
1. Child 6-12 years 2. Nocturnal Enuresis 3. Adolescent 13-18 years
Provide patient population that should be included in the study
Topical azelaic acid, salicylic acid, nicotinamide, sulphur, zinc and fruit acid (alpha‐hydroxy acid) for acne
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Acne 8. Young Adult 19-24 years 9. Birth to 1 mo 10. Aged 65-79 years 11. Adolescent 13-18 years
Provide patient population that should be included in the study
Corticosteroids as standalone or add‐on treatment for sore throat
1. Child, Preschool 2-5 years 2. Adult 19-44 years 3. Child 6-12 years 4. Sore Throat 5. Middle Aged 45-64 years 6. Young Adult 19-24 years 7. Adolescent 13-18 years
Provide patient population that should be included in the study
Inhaled mannitol for cystic fibrosis
1. Child, Preschool 2-5 years 2. Adult 19-44 years 3. Child 6-12 years 4. Middle Aged 45-64 years 5. Cystic Fibrosis 6. Young Adult 19-24 years 7. Adolescent 13-18 years
Provide patient population that should be included in the study
Normal saline (0.9% sodium chloride) versus heparin intermittent flushing for the prevention of occlusion in long‐term central venous catheters in infants and children
1. Child, Preschool 2-5 years 2. Child 6-12 years 3. Infant 1 to 23 mo 4. Birth to 1 mo 5. Central Venous Catheterisation 6. Adolescent 13-18 years
Provide patient population that should be included in the study
Oscillating devices for airway clearance in people with cystic fibrosis
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Cystic Fibrosis 8. Young Adult 19-24 years 9. Birth to 1 mo 10. Aged 65-79 years 11. Adolescent 13-18 years
Provide patient population that should be included in the study
Tonsillectomy versus tonsillotomy for obstructive sleep‐disordered breathing in children
1. Child, Preschool 2-5 years 2. Child 6-12 years 3. Breathing-related Sleep Disorder 4. Adolescent 13-18 years
Provide patient population that should be included in the study
Treating progressive disseminated histoplasmosis in people living with HIV
1. Child, Preschool 2-5 years 2. Adult 19-44 years 3. Child 6-12 years 4. Middle Aged 45-64 years 5. Progressive disseminated histoplasmosis 6. Young Adult 19-24 years 7. HIV infection 8. Adolescent 13-18 years
Provide patient population that should be included in the study
Clonazepam add‐on therapy for drug‐resistant epilepsy
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Partial Seizure 4. Drug Resistant Epilepsy 5. Middle Aged 45-64 years 6. Young Adult 19-24 years 7. Aged 65-79 years 8. Adolescent 13-18 years
Provide patient population that should be included in the study
Vitamin D, calcium or a combination of vitamin D and calcium for the treatment of nutritional rickets in children
1. Child, Preschool 2-5 years 2. Child 6-12 years 3. Nutritional rickets 4. Adolescent 13-18 years
Provide patient population that should be included in the study
Non‐invasive respiratory support for the management of transient tachypnea of the newborn
1. Transitory Tachypnea Of Newborn 2. Term infant (37-41 weeks) 3. Birth to 1 mo 4. Late Preterm Infant (34-36 weeks)
Provide patient population that should be included in the study
Interventions for fatigue in inflammatory bowel disease
1. Child, Preschool 2-5 years 2. Adult 19-44 years 3. Child 6-12 years 4. Middle Aged 45-64 years 5. Young Adult 19-24 years 6. Fatigue 7. Inflammatory Bowel Disease 8. Aged 65-79 years 9. Adolescent 13-18 years
Provide patient population that should be included in the study
Anthelmintic drugs for treating ascariasis
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Young Adult 19-24 years 8. Birth to 1 mo 9. Ascaris Lumbricoides Infection 10. Aged 65-79 years 11. Adolescent 13-18 years
Provide patient population that should be included in the study
Omega‐3 fatty acid supplementation for cystic fibrosis
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Cystic Fibrosis 8. Young Adult 19-24 years 9. Birth to 1 mo 10. Aged 65-79 years 11. Adolescent 13-18 years
Provide patient population that should be included in the study
Rinse‐free hand wash for reducing absenteeism among preschool and school children
1. Child, Preschool 2-5 years 2. Child 6-12 years 3. Adolescent 13-18 years
Provide patient population that should be included in the study
Agricultural and nutritional education interventions for reducing aflatoxin exposure to improve infant and child growth in low‐ and middle‐income countries
1. Child, Preschool 2-5 years 2. Child 6-12 years 3. Infant 1 to 23 mo 4. Birth to 1 mo 5. Adolescent 13-18 years
Provide patient population that should be included in the study
EEG for children with complex febrile seizures
1. Child, Preschool 2-5 years 2. Infant 1 to 23 mo 3. Birth to 1 mo 4. Complex Febrile Seizure
Provide patient population that should be included in the study
Clonidine for pain in non‐ventilated infants
1. Pain 2. Term infant (37-41 weeks) 3. Procedural Pain 4. Birth to 1 mo 5. Preterm Infant
Provide patient population that should be included in the study
Early versus late parenteral nutrition for critically ill term and late preterm infants
1. Term infant (37-41 weeks) 2. Critical Illness 3. Birth to 1 mo 4. Late Preterm Infant (34-36 weeks)
Provide patient population that should be included in the study
Exercise versus no exercise for the occurrence, severity, and duration of acute respiratory infections
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Acute Respiratory Infections 8. Young Adult 19-24 years 9. Birth to 1 mo 10. Aged 65-79 years 11. Chronic Disease Of Respiratory System 12. Adolescent 13-18 years
Provide patient population that should be included in the study
Antibiotic treatment for Burkholderia cepacia complex in people with cystic fibrosis experiencing a pulmonary exacerbation
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Child 6-12 years 4. Infant 1 to 23 mo 5. Cystic Fibrosis 6. Cystic Fibrosis Pulmonary Exacerbation 7. Aged 65-79 years 8. Adolescent 13-18 years 9. Adult 19-44 years 10. Burkholderia Cepacia Complex Infection 11. Middle Aged 45-64 years 12. Young Adult 19-24 years 13. Birth to 1 mo 14. Infective Pulmonary Exacerbation Of Cystic Fibrosis
Provide patient population that should be included in the study
Treatments for the prevention of Sudden Unexpected Death in Epilepsy (SUDEP)
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Epilepsy 8. Young Adult 19-24 years 9. Birth to 1 mo 10. Aged 65-79 years 11. Adolescent 13-18 years
Provide patient population that should be included in the study
Enteral lactoferrin supplementation for prevention of sepsis and necrotizing enterocolitis in preterm infants
1. Birth to 1 mo 2. Preterm Infant
Provide patient population that should be included in the study
Interventions for preventing and managing advanced liver disease in cystic fibrosis
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Young Adult 19-24 years 8. Birth to 1 mo 9. Aged 65-79 years 10. Liver Disease Due To Cystic Fibrosis 11. Adolescent 13-18 years
Provide patient population that should be included in the study
Physical therapies for postural abnormalities in people with cystic fibrosis
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Child 6-12 years 4. Infant 1 to 23 mo 5. Cystic Fibrosis 6. Kyphosis Of Thoracic Spine 7. Postural Scoliosis 8. Aged 65-79 years 9. Adolescent 13-18 years 10. Adult 19-44 years 11. Middle Aged 45-64 years 12. Young Adult 19-24 years 13. Birth to 1 mo
Provide patient population that should be included in the study
Glucocorticoid replacement regimens for treating congenital adrenal hyperplasia
1. Child, Preschool 2-5 years 2. Adult 19-44 years 3. Child 6-12 years 4. Middle Aged 45-64 years 5. Congenital Adrenal Hyperplasia 6. Young Adult 19-24 years 7. Adolescent 13-18 years
Provide patient population that should be included in the study
Sustained versus standard inflations during neonatal resuscitation to prevent mortality and improve respiratory outcomes
1. Term infant (37-41 weeks) 2. Intermittent Positive Pressure Breathing 3. Birth to 1 mo 4. Preterm Infant 5. Resuscitation
Provide patient population that should be included in the study
Diaphragm‐triggered non‐invasive respiratory support in preterm infants
1. Birth to 1 mo 2. Mechanical ventilation 3. Preterm Infant
Provide patient population that should be included in the study
Postnatal corticosteroids for transient tachypnoea of the newborn
1. Transitory Tachypnea Of Newborn 2. Term infant (37-41 weeks) 3. Birth to 1 mo 4. Late Preterm Infant (34-36 weeks)
Provide patient population that should be included in the study
Immunosuppressive agents for treating IgA nephropathy
1. Child, Preschool 2-5 years 2. Adult 19-44 years 3. Child 6-12 years 4. Middle Aged 45-64 years 5. IgA Nephropathy 6. Young Adult 19-24 years 7. Adolescent 13-18 years
Provide patient population that should be included in the study
Sclerotherapy versus sham or no intervention for primary prophylaxis of oesophageal variceal bleeding in children with chronic liver disease or portal vein thrombosis
1. Child, Preschool 2-5 years 2. Child 6-12 years 3. Chronic Liver Disease 4. Infant 1 to 23 mo 5. Birth to 1 mo 6. Portal Vein Thrombosis 7. Adolescent 13-18 years 8. Esophageal Varices
Provide patient population that should be included in the study
Probiotics for maintenance of remission in ulcerative colitis
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Ulcerative Colitis In Remission 7. Infant 1 to 23 mo 8. Young Adult 19-24 years 9. Aged 65-79 years 10. Adolescent 13-18 years
Provide patient population that should be included in the study
Home fortification of foods with multiple micronutrient powders for health and nutrition in children under two years of age
1. Infant 1 to 23 mo 2. Birth to 1 mo
Provide patient population that should be included in the study
Timing of hypertonic saline inhalation for cystic fibrosis
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Cystic Fibrosis 8. Young Adult 19-24 years 9. Birth to 1 mo 10. Aged 65-79 years 11. Adolescent 13-18 years
Provide patient population that should be included in the study
Different unfractionated heparin doses for preventing arterial thrombosis in children undergoing cardiac catheterization
1. Child, Preschool 2-5 years 2. Child 6-12 years 3. Congenital Heart Disease 4. Cardiac Catheterization 5. Infant 1 to 23 mo 6. Birth to 1 mo 7. Adolescent 13-18 years
Provide patient population that should be included in the study
Ibuprofen for the treatment of patent ductus arteriosus in preterm or low birth weight (or both) infants
1. Birth to 1 mo 2. Low Birth Weight Infant 3. Preterm Infant 4. Patent Ductus Arteriosus
Provide patient population that should be included in the study
Early versus late erythropoietin for preventing red blood cell transfusion in preterm and/or low birth weight infants
1. Birth to 1 mo 2. Low Birth Weight Infant 3. Preterm Infant
Provide patient population that should be included in the study
Surfactant for pulmonary haemorrhage in neonates
1. Pulmonary Hemorrhage 2. Term infant (37-41 weeks) 3. Birth to 1 mo 4. Intubation 5. Preterm Infant
Provide patient population that should be included in the study
Intravenous immunoglobulin for preventing infection in preterm and/or low birth weight infants
1. Birth to 1 mo 2. Low Birth Weight Infant 3. Preterm Infant
Provide patient population that should be included in the study
Paracetamol (acetaminophen) for prevention or treatment of pain in newborns
1. Neonate 2. Procedural Pain 3. Birth to 1 mo
Provide patient population that should be included in the study
Oral Janus kinase inhibitors for maintenance of remission in ulcerative colitis
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Ulcerative Colitis In Remission 7. Infant 1 to 23 mo 8. Young Adult 19-24 years 9. Birth to 1 mo 10. Aged 65-79 years 11. Adolescent 13-18 years
Provide patient population that should be included in the study
Interventions for chronic pruritus of unknown origin
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Generalized Pruritus Of Unknown Etiology 7. Infant 1 to 23 mo 8. Young Adult 19-24 years 9. Birth to 1 mo 10. Aged 65-79 years 11. Adolescent 13-18 years
Provide patient population that should be included in the study
Probiotics for people with cystic fibrosis
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Cystic Fibrosis 8. Young Adult 19-24 years 9. Birth to 1 mo 10. Aged 65-79 years 11. Adolescent 13-18 years
Provide patient population that should be included in the study
Improving vaccination uptake among adolescents
1. Adult 19-44 years 2. Child 6-12 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Adolescent 13-18 years
Provide patient population that should be included in the study
Hypertonic saline versus other intracranial pressure–lowering agents for people with acute traumatic brain injury
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Traumatic Brain Injury 7. Young Adult 19-24 years 8. Aged 65-79 years 9. Adolescent 13-18 years
Provide patient population that should be included in the study
Anti‐inflammatory medications for obstructive sleep apnoea in children
1. Child, Preschool 2-5 years 2. Child 6-12 years 3. Infant 1 to 23 mo 4. Obstructive Sleep Apnea Syndrome 5. Adolescent 13-18 years
Provide patient population that should be included in the study
Sclerotherapy versus beta‐blockers for primary prophylaxis of oesophageal variceal bleeding in children and adolescents with chronic liver disease or portal vein thrombosis
1. Child, Preschool 2-5 years 2. Child 6-12 years 3. Chronic Liver Disease 4. Infant 1 to 23 mo 5. Birth to 1 mo 6. Portal Vein Thrombosis 7. Adolescent 13-18 years 8. Esophageal Varices
Provide patient population that should be included in the study
Topical antiseptics for chronic suppurative otitis media
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Child 6-12 years 4. Infant 1 to 23 mo 5. Ear Drum Perforation 6. Chronic Disease Of Ear 7. Aged 65-79 years 8. Adolescent 13-18 years 9. Otorrhea 10. Adult 19-44 years 11. Middle Aged 45-64 years 12. Young Adult 19-24 years 13. Birth to 1 mo 14. Chronic Suppurative Otitis Media
Provide patient population that should be included in the study
Drug treatment for spinal muscular atrophy types II and III
1. Child, Preschool 2-5 years 2. Adult 19-44 years 3. Child 6-12 years 4. Middle Aged 45-64 years 5. Spinal Muscular Atrophy, Type 2 6. Spinal Muscular Atrophy, Type 3 7. Infant 1 to 23 mo 8. Young Adult 19-24 years 9. Adolescent 13-18 years
Provide patient population that should be included in the study
Antibiotics versus topical antiseptics for chronic suppurative otitis media
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Child 6-12 years 4. Infant 1 to 23 mo 5. Ear Drum Perforation 6. Chronic Disease Of Ear 7. Aged 65-79 years 8. Adolescent 13-18 years 9. Otorrhea 10. Adult 19-44 years 11. Middle Aged 45-64 years 12. Young Adult 19-24 years 13. Birth to 1 mo 14. Chronic Suppurative Otitis Media
Provide patient population that should be included in the study
Caregiver involvement in interventions for improving children's dietary intake and physical activity behaviors
1. Child, Preschool 2-5 years 2. Child 6-12 years 3. Adolescent 13-18 years
Provide patient population that should be included in the study
Topical antibiotics for chronic suppurative otitis media
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Child 6-12 years 4. Infant 1 to 23 mo 5. Ear Drum Perforation 6. Chronic Disease Of Ear 7. Aged 65-79 years 8. Adolescent 13-18 years 9. Otorrhea 10. Adult 19-44 years 11. Middle Aged 45-64 years 12. Young Adult 19-24 years 13. Birth to 1 mo 14. Chronic Suppurative Otitis Media
Provide patient population that should be included in the study
Decompressive craniectomy for the treatment of high intracranial pressure in closed traumatic brain injury
1. Child, Preschool 2-5 years 2. Adult 19-44 years 3. Child 6-12 years 4. Middle Aged 45-64 years 5. Traumatic Brain Injury 6. Infant 1 to 23 mo 7. Young Adult 19-24 years 8. Adolescent 13-18 years
Provide patient population that should be included in the study
Tonsillectomy for periodic fever, aphthous stomatitis, pharyngitis and cervical adenitis syndrome (PFAPA)
1. Child, Preschool 2-5 years 2. Child 6-12 years 3. Infant 1 to 23 mo 4. Pfapa Syndrome 5. Birth to 1 mo 6. Adolescent 13-18 years
Provide patient population that should be included in the study
Racecadotril for acute diarrhoea in children
1. Child, Preschool 2-5 years 2. Acute Diarrhea 3. Child 6-12 years 4. Infant 1 to 23 mo 5. Birth to 1 mo 6. Adolescent 13-18 years
Provide patient population that should be included in the study
Equivalent schedules of intradermal fractional dose versus intramuscular full dose of inactivated polio vaccine for prevention of poliomyelitis
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Young Adult 19-24 years 8. Birth to 1 mo 9. Aged 65-79 years 10. Healthy 11. Adolescent 13-18 years
Provide patient population that should be included in the study
Treatments for preventing recurrence of infection with Pseudomonas aeruginosa in people with cystic fibrosis
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Cystic Fibrosis 8. Young Adult 19-24 years 9. Birth to 1 mo 10. Aged 65-79 years 11. Infection due to Pseudomonas Aeruginosa 12. Adolescent 13-18 years
Provide patient population that should be included in the study
Prophylactic antibiotics for penetrating abdominal trauma: duration of use and antibiotic choice
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Young Adult 19-24 years 8. Birth to 1 mo 9. Penetrating abdominal trauma 10. Aged 65-79 years 11. Adolescent 13-18 years
Provide patient population that should be included in the study
Interventions for managing halitosis
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Halitosis 6. Aged 65-79 years 7. Adolescent 13-18 years
Provide patient population that should be included in the study
Drug treatment for spinal muscular atrophy type I
1. Child, Preschool 2-5 years 2. Infant 1 to 23 mo 3. Spinal Muscular Atrophy, Type 1 4. Birth to 1 mo
Provide patient population that should be included in the study
Iron therapy for preoperative anaemia
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Anemia 5. Surgery 6. Young Adult 19-24 years 7. Aged 65-79 years
Provide patient population that should be included in the study
Primary closure versus delayed or no closure for traumatic wounds due to mammalian bite
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Mammal Bite Wound 6. Middle Aged 45-64 years 7. Infant 1 to 23 mo 8. Young Adult 19-24 years 9. Birth to 1 mo 10. Aged 65-79 years 11. Adolescent 13-18 years
Provide patient population that should be included in the study
Corticosteroids for treating sepsis in children and adults
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Young Adult 19-24 years 8. Birth to 1 mo 9. Sepsis 10. Aged 65-79 years 11. Adolescent 13-18 years
Provide patient population that should be included in the study
Beginning reading interventions for children and adolescents with intellectual disability
1. Child, Preschool 2-5 years 2. Child 6-12 years 3. Young Adult 19-24 years 4. Intellectual Disability 5. Adolescent 13-18 years
Provide patient population that should be included in the study
Sequential inactivated (IPV) and live oral (OPV) poliovirus vaccines for preventing poliomyelitis
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Young Adult 19-24 years 8. Birth to 1 mo 9. Aged 65-79 years 10. Healthy 11. Adolescent 13-18 years
Provide patient population that should be included in the study
Parent training programmes for managing infantile colic
1. Infant 1 to 23 mo 2. Infantile Colic 3. Birth to 1 mo
Provide patient population that should be included in the study
Intravenous immunoglobulins for epilepsy
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Epilepsy 8. Young Adult 19-24 years 9. Birth to 1 mo 10. Aged 65-79 years 11. Adolescent 13-18 years
Provide patient population that should be included in the study
Video feedback for parental sensitivity and attachment security in children under five years
1. Child, Preschool 2-5 years 2. Infant 1 to 23 mo 3. Attachment Security 4. Birth to 1 mo 5. Parental Sensitivity
Provide patient population that should be included in the study
Positive expiratory pressure physiotherapy for airway clearance in people with cystic fibrosis
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Cystic Fibrosis 8. Young Adult 19-24 years 9. Birth to 1 mo 10. Aged 65-79 years 11. Adolescent 13-18 years
Provide patient population that should be included in the study
Fluorides for preventing early tooth decay (demineralised lesions) during fixed brace treatment
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Young Adult 19-24 years 8. Birth to 1 mo 9. Requires Fixed Orthodontic Appliance 10. Aged 65-79 years 11. Adolescent 13-18 years
Provide patient population that should be included in the study
Human milk‐derived fortifier versus bovine milk‐derived fortifier for prevention of mortality and morbidity in preterm neonates
1. Enteral nutrition 2. Birth to 1 mo 3. Preterm Infant
Provide patient population that should be included in the study
Intranasal corticosteroids for non‐allergic rhinitis
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Child 6-12 years 4. Middle Aged 45-64 years 5. Young Adult 19-24 years 6. Aged 65-79 years 7. Adolescent 13-18 years 8. Non-allergic Rhinitis
Provide patient population that should be included in the study
Interventions to reduce Staphylococcus aureus in the management of eczema
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Staphylococcal Infections 4. Adult 19-44 years 5. Child 6-12 years 6. Middle Aged 45-64 years 7. Atopic Dermatitis 8. Young Adult 19-24 years 9. Eczema 10. Aged 65-79 years 11. Adolescent 13-18 years
Provide patient population that should be included in the study
Stopping enteral feeds for prevention of transfusion‐associated necrotising enterocolitis in preterm infants
1. Blood Transfusion 2. Enteral nutrition 3. Birth to 1 mo 4. Very Low Birth Weight Infant 5. Intensive Care 6. Preterm Infant
Provide patient population that should be included in the study
Medical and surgical interventions for the treatment of urinary stones in children
1. Child, Preschool 2-5 years 2. Child 6-12 years 3. Infant 1 to 23 mo 4. Urolithiasis 5. Birth to 1 mo 6. Adolescent 13-18 years
Provide patient population that should be included in the study
Botulinum toxin type A in the treatment of lower limb spasticity in children with cerebral palsy
1. Child, Preschool 2-5 years 2. Child 6-12 years 3. Infant 1 to 23 mo 4. Lower Limb Spasticity 5. Young Adult 19-24 years 6. Birth to 1 mo 7. Cerebral Palsy 8. Adolescent 13-18 years
Provide patient population that should be included in the study
Valproate for acute mania
1. Adult 19-44 years 2. Middle Aged 45-64 years 3. Bipolar Disorder 4. Young Adult 19-24 years 5. Aged 65-79 years 6. Adolescent 13-18 years
Provide patient population that should be included in the study
Antioxidant supplementation for lung disease in cystic fibrosis
1. Cystic Fibrosis 2. Lung disorder
Provide patient population that should be included in the study
Inhaled steroids with and without regular formoterol for asthma: serious adverse events
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Young Adult 19-24 years 7. Aged 65-79 years 8. Adolescent 13-18 years 9. Asthma
Provide patient population that should be included in the study
Interventions to improve disposal of child faeces for preventing diarrhoea and soil‐transmitted helminth infection
1. Child, Preschool 2-5 years 2. Child 6-12 years 3. Infant 1 to 23 mo 4. Birth to 1 mo 5. Faeces 6. Adolescent 13-18 years
Provide patient population that should be included in the study
Conservative interventions for treating functional daytime urinary incontinence in children
1. Child, Preschool 2-5 years 2. Child 6-12 years 3. Functional Urinary Incontinence 4. Adolescent 13-18 years
Provide patient population that should be included in the study
Calcium supplementation commencing before or early in pregnancy, for preventing hypertensive disorders of pregnancy
1. Adult 19-44 years 2. Middle Aged 45-64 years 3. Young Adult 19-24 years 4. Pregnancy 5. Adolescent 13-18 years
Provide patient population that should be included in the study
Public health deworming programmes for soil‐transmitted helminths in children living in endemic areas
1. Child, Preschool 2-5 years 2. Child 6-12 years 3. Infant 1 to 23 mo 4. Birth to 1 mo 5. Adolescent 13-18 years
Provide patient population that should be included in the study
Oral non‐steroidal anti‐inflammatory drug therapy for lung disease in cystic fibrosis
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Cystic Fibrosis 7. Young Adult 19-24 years 8. Aged 65-79 years 9. Adolescent 13-18 years
Provide patient population that should be included in the study
Respiratory muscle training in children and adults with neuromuscular disease
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Child 6-12 years 4. Infant 1 to 23 mo 5. Motor Neuron Disease 6. Neuromuscular Disorders 7. Aged 65-79 years 8. Adolescent 13-18 years 9. Adult 19-44 years 10. Middle Aged 45-64 years 11. Peripheral Nerve Disease 12. Young Adult 19-24 years 13. Disorder Of Muscle 14. Birth to 1 mo 15. Neuromuscular Junction Disorder
Provide patient population that should be included in the study
Homeopathy for treatment of irritable bowel syndrome
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Young Adult 19-24 years 8. Irritable bowel syndrome 9. Birth to 1 mo 10. Aged 65-79 years 11. Adolescent 13-18 years
Provide patient population that should be included in the study
Altering the availability or proximity of food, alcohol, and tobacco products to change their selection and consumption
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Young Adult 19-24 years 8. Birth to 1 mo 9. Aged 65-79 years 10. Adolescent 13-18 years
Provide patient population that should be included in the study
Once‐daily versus multiple‐daily dosing with intravenous aminoglycosides for cystic fibrosis
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Cystic Fibrosis 8. Young Adult 19-24 years 9. Birth to 1 mo 10. Aged 65-79 years 11. Adolescent 13-18 years
Provide patient population that should be included in the study
Fetal biometry for guiding the medical management of women with gestational diabetes mellitus for improving maternal and perinatal health
1. Adult 19-44 years 2. Middle Aged 45-64 years 3. Young Adult 19-24 years 4. Pregnancy 5. Gestational Diabetes Mellitus 6. Adolescent 13-18 years
Provide patient population that should be included in the study
Chlorhexidine bathing of the critically ill for the prevention of hospital‐acquired infection
1. Child, Preschool 2-5 years 2. Adult 19-44 years 3. Child 6-12 years 4. Middle Aged 45-64 years 5. Young Adult 19-24 years 6. Critical Illness 7. Intensive Care 8. Adolescent 13-18 years
Provide patient population that should be included in the study
Contact tracing strategies in household and congregate environments to identify cases of tuberculosis in low‐ and moderate‐incidence populations
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Tuberculosis 7. Infant 1 to 23 mo 8. Young Adult 19-24 years 9. Birth to 1 mo 10. Aged 65-79 years 11. Adolescent 13-18 years
Provide patient population that should be included in the study
Sulthiame add‐on therapy for epilepsy
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Epilepsy 8. Young Adult 19-24 years 9. Birth to 1 mo 10. Aged 65-79 years 11. Adolescent 13-18 years
Provide patient population that should be included in the study
TNF‐α blockers for the treatment of Kawasaki disease in children
1. Child, Preschool 2-5 years 2. Child 6-12 years 3. Infant 1 to 23 mo 4. Kawasaki's syndrome 5. Birth to 1 mo 6. Adolescent 13-18 years
Provide patient population that should be included in the study
Prebiotics for the prevention of hyperbilirubinaemia in neonates
1. Neonate 2. Birth to 1 mo
Provide patient population that should be included in the study
eHealth interventions for people with chronic kidney disease
1. Child, Preschool 2-5 years 2. Adult 19-44 years 3. Child 6-12 years 4. Middle Aged 45-64 years 5. Young Adult 19-24 years 6. Chronic Kidney Disease 7. Adolescent 13-18 years
Provide patient population that should be included in the study
Azathioprine and 6‐mercaptopurine for maintenance of surgically‐induced remission in Crohn's disease
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Crohn's Disease In Remission 7. Infant 1 to 23 mo 8. Surgery 9. Young Adult 19-24 years 10. Birth to 1 mo 11. Aged 65-79 years 12. Adolescent 13-18 years
Provide patient population that should be included in the study
Protein hydrolysate versus standard formula for preterm infants
1. Enteral nutrition 2. Infant Formula 3. Birth to 1 mo 4. Preterm Infant
Provide patient population that should be included in the study
Interventions for preventing obesity in children
1. Child, Preschool 2-5 years 2. Child 6-12 years 3. Adolescent 13-18 years
Provide patient population that should be included in the study
Buffered solutions versus 0.9% saline for resuscitation in critically ill adults and children
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Young Adult 19-24 years 8. Critical Illness 9. Birth to 1 mo 10. Aged 65-79 years 11. Resuscitation 12. Adolescent 13-18 years
Provide patient population that should be included in the study
Community first responders for out‐of‐hospital cardiac arrest in adults and children
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Young Adult 19-24 years 8. Cardiac Arrest 9. Birth to 1 mo 10. Aged 65-79 years 11. Adolescent 13-18 years
Provide patient population that should be included in the study
Carbamazepine versus phenytoin monotherapy for epilepsy: an individual participant data review
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Partial Seizure 6. Middle Aged 45-64 years 7. Infant 1 to 23 mo 8. Young Adult 19-24 years 9. Birth to 1 mo 10. Aged 65-79 years 11. Adolescent 13-18 years 12. Generalized Seizure
Provide patient population that should be included in the study
Genetic testing for prevention of severe drug‐induced skin rash
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Young Adult 19-24 years 8. Birth to 1 mo 9. Aged 65-79 years 10. Adolescent 13-18 years
Provide patient population that should be included in the study
Interventions for morphea
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Morphea 4. Adult 19-44 years 5. Child 6-12 years 6. Middle Aged 45-64 years 7. Infant 1 to 23 mo 8. Young Adult 19-24 years 9. Birth to 1 mo 10. Aged 65-79 years 11. Adolescent 13-18 years
Provide patient population that should be included in the study
Singing as an adjunct therapy for children and adults with cystic fibrosis
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Cystic Fibrosis 8. Young Adult 19-24 years 9. Birth to 1 mo 10. Aged 65-79 years 11. Adolescent 13-18 years
Provide patient population that should be included in the study
Inositol in preterm infants at risk for or having respiratory distress syndrome
1. Birth to 1 mo 2. Low Birth Weight Infant 3. Preterm Infant
Provide patient population that should be included in the study
Interventions for treating neuropathic pain in people with sickle cell disease
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Young Adult 19-24 years 8. Neuropathic Pain 9. Birth to 1 mo 10. Aged 65-79 years 11. Hemoglobin SS Disease 12. Adolescent 13-18 years
Provide patient population that should be included in the study
Inhaled corticosteroids for cystic fibrosis
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Cystic Fibrosis 8. Young Adult 19-24 years 9. Birth to 1 mo 10. Aged 65-79 years 11. Adolescent 13-18 years
Provide patient population that should be included in the study
Pharmacological interventions for prevention and treatment of upper gastrointestinal bleeding in newborn infants
1. Term infant (37-41 weeks) 2. Birth to 1 mo 3. Preterm Infant
Provide patient population that should be included in the study
Computer and mobile technology interventions to promote medication adherence and disease management in people with thalassemia
1. Child, Preschool 2-5 years 2. Adult 19-44 years 3. Child 6-12 years 4. Middle Aged 45-64 years 5. Young Adult 19-24 years 6. Thalassemia 7. Adolescent 13-18 years
Provide patient population that should be included in the study
Banked preterm versus banked term human milk to promote growth and development in very low birth weight infants
1. Birth to 1 mo 2. Very Low Birth Weight Infant
Provide patient population that should be included in the study
Surgery for epilepsy
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Drug Resistant Epilepsy 6. Middle Aged 45-64 years 7. Young Adult 19-24 years 8. Aged 65-79 years 9. Adolescent 13-18 years 10. Generalized Seizure
Provide patient population that should be included in the study
Radix Sophorae flavescentis versus other drugs or herbs for chronic hepatitis B
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Chronic hepatitis B 8. Young Adult 19-24 years 9. Birth to 1 mo 10. Aged 65-79 years 11. Adolescent 13-18 years
Provide patient population that should be included in the study
Social skills training for attention deficit hyperactivity disorder (ADHD) in children aged 5 to 18 years
1. Child, Preschool 2-5 years 2. Child 6-12 years 3. Attention Deficit Hyperactivity Disorder 4. Adolescent 13-18 years
Provide patient population that should be included in the study
Oral 5‐aminosalicylic acid for maintenance of surgically‐induced remission in Crohn's disease
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Crohn's Disease 6. Middle Aged 45-64 years 7. Infant 1 to 23 mo 8. Young Adult 19-24 years 9. Birth to 1 mo 10. Aged 65-79 years 11. Adolescent 13-18 years
Provide patient population that should be included in the study
Probiotics for preventing acute otitis media in children
1. Child, Preschool 2-5 years 2. Child 6-12 years 3. Infant 1 to 23 mo 4. Birth to 1 mo 5. Acute Otitis Media 6. Adolescent 13-18 years
Provide patient population that should be included in the study
Enzyme replacement therapy with laronidase (Aldurazyme®) for treating mucopolysaccharidosis type I
1. Child, Preschool 2-5 years 2. Child 6-12 years 3. Infant 1 to 23 mo 4. Hemopoietic Stem Cell Transplant 5. Birth to 1 mo 6. Mucopolysaccharidosis Type I 7. Adolescent 13-18 years
Provide patient population that should be included in the study
Inhaled corticosteroids in children with persistent asthma: effects of different drugs and delivery devices on growth
1. Child, Preschool 2-5 years 2. Child 6-12 years 3. Infant 1 to 23 mo 4. Birth to 1 mo 5. Wheezing 6. Adolescent 13-18 years 7. Asthma
Provide patient population that should be included in the study
Lipid emulsions for parenterally fed preterm infants
1. Parenteral Nutrition Associated Liver Disease 2. Neonatal cholestasis 3. Surgery 4. Birth to 1 mo 5. Parenteral nutrition 6. Preterm Infant
Provide patient population that should be included in the study
Lipid emulsions for parenterally fed term and late preterm infants
1. Parenteral Nutrition Associated Liver Disease 2. Term infant (37-41 weeks) 3. Neonatal cholestasis 4. Surgery 5. Birth to 1 mo 6. Parenteral nutrition 7. Late Preterm Infant (34-36 weeks)
Provide patient population that should be included in the study
Lithium for acute mania
1. Adult 19-44 years 2. Middle Aged 45-64 years 3. Bipolar Disorder 4. Young Adult 19-24 years 5. Mania
Provide patient population that should be included in the study
Interventions for promoting participation in shared decision‐making for children and adolescents with cystic fibrosis
1. Child, Preschool 2-5 years 2. Child 6-12 years 3. Infant 1 to 23 mo 4. Cystic Fibrosis 5. Birth to 1 mo 6. Adolescent 13-18 years
Provide patient population that should be included in the study
Ready‐to‐use therapeutic food (RUTF) for home‐based nutritional rehabilitation of severe acute malnutrition in children from six months to five years of age
1. Child, Preschool 2-5 years 2. Severe Acute Malnutrition 3. Infant 1 to 23 mo
Provide patient population that should be included in the study
Enteral lactoferrin for the treatment of sepsis and necrotizing enterocolitis in neonates
1. Neonate 2. Necrotizing Enterocolitis 3. Birth to 1 mo 4. Sepsis 5. Antibiotic Therapy
Provide patient population that should be included in the study
Preventive lipid‐based nutrient supplements given with complementary foods to infants and young children 6 to 23 months of age for health, nutrition, and developmental outcomes
1. Infant 1 to 23 mo 2. Birth to 1 mo 3. Healthy
Provide patient population that should be included in the study
Family therapy approaches for anorexia nervosa
1. Child 6-12 years 2. Anorexia Nervosa 3. Young Adult 19-24 years 4. Adolescent 13-18 years
Provide patient population that should be included in the study
Probiotics for the prevention of pediatric antibiotic‐associated diarrhea
1. Child, Preschool 2-5 years 2. Child 6-12 years 3. Infant 1 to 23 mo 4. Birth to 1 mo 5. Antibiotic Therapy 6. Adolescent 13-18 years
Provide patient population that should be included in the study
MVA85A vaccine to enhance BCG for preventing tuberculosis
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Young Adult 19-24 years 8. Birth to 1 mo 9. HIV infection 10. Aged 65-79 years 11. Healthy 12. Adolescent 13-18 years
Provide patient population that should be included in the study
Haloperidol discontinuation for people with schizophrenia
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Schizophrenic Related Disorders 6. Schizophrenia 7. Aged 65-79 years
Provide patient population that should be included in the study
Eradication therapy for Burkholderia cepacia complex in people with cystic fibrosis
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Burkholderia Cepacia Complex Infection 6. Middle Aged 45-64 years 7. Infant 1 to 23 mo 8. Cystic Fibrosis 9. Young Adult 19-24 years 10. Birth to 1 mo 11. Aged 65-79 years 12. Adolescent 13-18 years
Provide patient population that should be included in the study
Medical treatment for botulism
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Botulism 7. Infant 1 to 23 mo 8. Young Adult 19-24 years 9. Birth to 1 mo 10. Aged 65-79 years 11. Adolescent 13-18 years
Provide patient population that should be included in the study
First aid glucose administration routes for symptomatic hypoglycaemia
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Young Adult 19-24 years 7. Diabetes Mellitus 8. Hypoglycemia 9. Aged 65-79 years 10. Healthy 11. Adolescent 13-18 years
Provide patient population that should be included in the study
Home use of interdental cleaning devices, in addition to toothbrushing, for preventing and controlling periodontal diseases and dental caries
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Young Adult 19-24 years 8. Birth to 1 mo 9. Aged 65-79 years 10. Adolescent 13-18 years
Provide patient population that should be included in the study
Psychological therapies (remotely delivered) for the management of chronic and recurrent pain in children and adolescents
1. Child, Preschool 2-5 years 2. Child 6-12 years 3. Headache 4. Infant 1 to 23 mo 5. Birth to 1 mo 6. Recurrent Abdominal Pain 7. Adolescent 13-18 years 8. Chronic Pain
Provide patient population that should be included in the study
Long‐term antibiotics for preventing recurrent urinary tract infection in children
1. Child, Preschool 2-5 years 2. Child 6-12 years 3. Infant 1 to 23 mo 4. Birth to 1 mo 5. Urinary Tract Infection 6. Adolescent 13-18 years
Provide patient population that should be included in the study
Constraint‐induced movement therapy in children with unilateral cerebral palsy
1. Child, Preschool 2-5 years 2. Child 6-12 years 3. Infant 1 to 23 mo 4. Hemiplegic Cerebral Palsy 5. Young Adult 19-24 years 6. Birth to 1 mo 7. Adolescent 13-18 years
Provide patient population that should be included in the study
Supplemental perioperative intravenous crystalloids for postoperative nausea and vomiting
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Surgery 8. Young Adult 19-24 years 9. General Anesthesia 10. Aged 65-79 years 11. Adolescent 13-18 years
Provide patient population that should be included in the study
Family‐based prevention programmes for alcohol use in young people
1. Child, Preschool 2-5 years 2. Child 6-12 years 3. Adolescent 13-18 years
Provide patient population that should be included in the study
Multiple‐micronutrient supplementation for women during pregnancy
1. Adult 19-44 years 2. Pregnant 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Adolescent 13-18 years
Provide patient population that should be included in the study
Probiotics to prevent infantile colic
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Child 6-12 years 4. Pregnant 5. Infant 1 to 23 mo 6. Aged 65-79 years 7. Adolescent 13-18 years 8. Adult 19-44 years 9. Middle Aged 45-64 years 10. Young Adult 19-24 years 11. Birth to 1 mo 12. Breastfeeding 13. Healthy
Provide patient population that should be included in the study
Dental cavity liners for Class I and Class II resin‐based composite restorations
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Young Adult 19-24 years 8. Birth to 1 mo 9. Dental Restoration Present 10. Aged 65-79 years 11. Adolescent 13-18 years
Provide patient population that should be included in the study
Fluoride toothpastes of different concentrations for preventing dental caries
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Young Adult 19-24 years 8. Aged 65-79 years 9. Adolescent 13-18 years
Provide patient population that should be included in the study
Physical exercise training for type 3 spinal muscular atrophy
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Child 6-12 years 4. Middle Aged 45-64 years 5. Spinal Muscular Atrophy, Type 3 6. Young Adult 19-24 years 7. Aged 65-79 years 8. Adolescent 13-18 years
Provide patient population that should be included in the study
The use of ultrasound guidance for perioperative neuraxial and peripheral nerve blocks in children
1. Child, Preschool 2-5 years 2. Child 6-12 years 3. Infant 1 to 23 mo 4. Surgery 5. Administration Of Anesthesia 6. Birth to 1 mo 7. Adolescent 13-18 years